Genetix Biotherapeutics is the rebranded gene therapy company formerly known as bluebird bio, owned by investment funds managed by The Carlyle Group and SK Capital Partners. It manufactures and sells lentiviral gene therapies for severe genetic blood and neurological disorders.
It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million.